Leomics Associates is an undisputed industry leader and provider of consulting services in clinical molecular diagnostic testing. Since Leomics founder Dr. Leon helped launch the field of molecular diagnostic testing and related services in 1990, it has emerged as a growth business, generating more than 30 million tests performed annually in the United States, and $3 billion in revenues in the services business. Today, Leomics provides high end consulting services for this fast growing industry.
Fast Facts
Diagnostics products are usually divided into "core" or "esoteric" products. Leomics provides consulting services for both of these product types.
The core products include typical routine clinical tests such as blood and slide analysis, as well as testing for cholesterol, liver enzymes, PSA, pathology, and Pap smear.
The esoteric tests are either rarely performed, of medium to high complexity, costly, or a combination of all three. The esoteric testing market comprises approximately 20% of the total market.
Within the esoteric testing area two major testing categories: molecular, and all other esoteric tests. Leomics provides services and consulting for companies and labs developing both of these test types.
These types of tests include the analysis of DNA, RNA (nucleic acids) micro RNAs, and complex proteomic or metabolomic pattern array based tests. In the foreseeable future, proteomic/metabolomic tests may form their own sub-category. However, they are presently included among the general group of molecular diagnostics. This classification probably exists because these tests have bioinformatics, sample preparation, and reimbursement issues in common with the nucleic acid tests.
Molecular diagnostics is the fastest growing segment of clinical testing today, comprising 3-4 times the growth of the core business, depending on the country.
In the US, the this sector is predicted to expand to 30% of the total service diagnostics revenues by 2015. Through our consulting services, we position you to tap into this profitable market segment.
As part of our consulting services, we analyze the molecular diagnostics space by sub-dividing it into molecular tissue pathology, which is basically molecular DNA, RNA by PCR/real time PCR or fluorescent in situ hybridization on tissue (FISH). These tests involve a different setting (the pathology lab), and a different culture (pathologists, cytopathologists). They also have different and quite complex requirements for success.
The world of molecular diagnostics is changing. Traditionally, it has only included testing for infectious disease (such as HIV and HPV); genetics (such as cystic fibrosis, and BRCA 1 and 2); and, to a lesser extent, oncology (such as leukemia and lymphoma molecular classification). However, trends are emerging based on new molecular tests for the diagnosis and management of several diseases beyond cancer, infectious disease and genetics. This includes testing for immunity, metabolism, the central nervous system and cardiovascular function.
In addition, new technologies which analyze multiple genes (10-10,000), single cells or new metabolites are now available, providing rapid information to better classify or manage disease.
Leomics provides high level consulting services, arming labs and testing facilities with the action plan, connections, and experience necessary to bring new tests and services to the market.